Advertisement
Letter to the Editor| Volume 19, ISSUE 2, P182, February 2018

Polypharmacy, An Unfinished Term

      It is known that the worldwide population is aging, and the number of elderly people is at an all-time high. Elderly people have a high burden of chronic diseases associated with increased risk of hospitalization and death.
      • Nunes B.P.
      • Flores T.R.
      • Mielke G.I.
      • et al.
      Multimorbidity and mortality in older adults: A systematic review and meta-analysis.
      This situation results in the prescription of an excessive number of drugs, which increases the risk of drug interactions and adverse drug reactions.
      • Gomez Aguirre N.
      • Caudevilla Martinez A.
      • Bellostas Munoz L.
      • et al.
      Polypathology, polypharmacy, medication regimen complexity and drug therapy appropriateness.
      • Carroll C.
      • Hassanin A.
      Polypharmacy in the elderly—When good drugs lead to bad outcomes: A teachable moment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Nunes B.P.
        • Flores T.R.
        • Mielke G.I.
        • et al.
        Multimorbidity and mortality in older adults: A systematic review and meta-analysis.
        Arch Gerontol Geriatr. 2016; 67: 130-138
        • Gomez Aguirre N.
        • Caudevilla Martinez A.
        • Bellostas Munoz L.
        • et al.
        Polypathology, polypharmacy, medication regimen complexity and drug therapy appropriateness.
        Rev Clin Esp. 2017; 217: 289-295
        • Carroll C.
        • Hassanin A.
        Polypharmacy in the elderly—When good drugs lead to bad outcomes: A teachable moment.
        JAMA Intern Med. 2017; 177: 871
        • Stewart D.
        • Mair A.
        • Wilson M.
        • et al.
        Guidance to manage inappropriate polypharmacy in older people: Systematic review and future developments.
        Expert Opin Drug Saf. 2017; 16: 203-213
        • Levy H.B.
        Polypharmacy reduction strategies: Tips on incorporating American Geriatrics Society Beers and Screening Tool of Older People's Prescriptions Criteria.
        Clin Geriatr Med. 2017; 33: 177-187
        • Jokanovic N.
        • Tan E.C.
        • Dooley M.J.
        • et al.
        Prevalence and factors associated with polypharmacy in long-term care facilities: A systematic review.
        J Am Med Dir Assoc. 2015; 16: 535.e1-535.e12
        • Masnoon N.
        • Shakib S.
        • Kalisch-Ellett L.
        • Caughey G.E.
        What is polypharmacy? A systematic review of definitions.
        BMC Geriatr. 2017; 17: 230
        • Nisly N.L.
        • Gryzlak B.M.
        • Zimmerman M.B.
        • Wallace R.B.
        Dietary supplement polypharmacy: An unrecognized public health problem?.
        Evid Based Complement Alternat Med. 2010; 7: 107-113
        • Maher R.L.
        • Hanlon J.
        • Hajjar E.R.
        Clinical consequences of polypharmacy in elderly.
        Expert Opin Drug Saf. 2014; 13: 57-65
        • Machado-Alba J.E.
        • Gaviria-Mendoza A.
        • Machado-Duque M.E.
        • Chica L.
        Deprescribing: A new goal focused on the patient.
        Expert Opin Drug Saf. 2017; 16: 111-112